Los Angeles-based Cedars-Sinai will receive up to $5,054,235 from the federal ARPA-H CATALYST program to develop an AI platform designed to predict drug toxicity before clinical trials begin.
The platform will use AI to analyze “patient avatars” — organ-on-chip systems derived from human stem cells — to forecast how medications may affect human organs over time. The goal is to reduce clinical trial failures caused by adverse drug reactions, which account for more than 30% of trial shutdowns, according to a Jan. 13 news release from the health system.
The AI system is powered by millions of de-identified data points from Cedars-Sinai’s EHRs and incorporates patient-specific factors such as age, comorbidities and medication use to model evolving drug risk.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
